

Michelle S Miller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8125297/publications.pdf>

Version: 2024-02-01

17
papers

775
citations

687220

13
h-index

839398

18
g-index

18
all docs

18
docs citations

18
times ranked

1160
citing authors

#	ARTICLE	IF	CITATIONS
1	Structure of the BAK-activating antibody 7D10 bound to BAK reveals an unexpected role for the $\hat{1}\pm 1\hat{1}\pm 2$ loop in BAK activation. <i>Cell Death and Differentiation</i> , 2022, 29, 1757-1768.	5.0	4
2	Bispecific antibodies targeting mutant <i>RAS</i> neoantigens. <i>Science Immunology</i> , 2021, 6, .	5.6	106
3	Targeting a neoantigen derived from a common <i>TP53</i> mutation. <i>Science</i> , 2021, 371, .	6.0	194
4	Structure of detergent-activated BAK dimers derived from the inert monomer. <i>Molecular Cell</i> , 2021, 81, 2123-2134.e5.	4.5	26
5	Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. <i>Nature Communications</i> , 2021, 12, 5271.	5.8	17
6	An engineered antibody fragment targeting mutant $\hat{2}$ -catenin via major histocompatibility complex I neoantigen presentation. <i>Journal of Biological Chemistry</i> , 2019, 294, 19322-19334.	1.6	15
7	Structural Determinants of Isoform Selectivity in PI3K Inhibitors. <i>Biomolecules</i> , 2019, 9, 82.	1.8	55
8	Getting the Most Out of Your Crystals: Data Collection at the New High-Flux, Microfocus MX Beamlines at NSLS-II. <i>Molecules</i> , 2019, 24, 496.	1.7	13
9	Identification of allosteric binding sites for PI3K $\hat{1}\pm$ oncogenic mutant specific inhibitor design. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 1481-1486.	1.4	24
10	Rapid PD-L1 detection in tumors with PET using a highly specific peptide. <i>Biochemical and Biophysical Research Communications</i> , 2017, 483, 258-263.	1.0	132
11	Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase $\hat{1}\pm$ that are critical for catalysis and substrate recognition. <i>Journal of Biological Chemistry</i> , 2017, 292, 13541-13550.	1.6	36
12	Development of single and mixed isoform selectivity PI3K $\hat{1}$ inhibitors by targeting Asn836 of PI3K $\hat{1}$. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4790-4794.	1.0	11
13	Structural basis of nSH2 regulation and lipid binding in PI3K $\hat{1}\pm$. <i>Oncotarget</i> , 2014, 5, 5198-5208.	0.8	62
14	Regioselective synthesis of 5- and 6-methoxybenzimidazole-1,3,5-triazines as inhibitors of phosphoinositide 3-kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 802-805.	1.0	13
15	Pyridinylquinazolines Selectively Inhibit Human Methionine Aminopeptidase-1 in Cells. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3996-4016.	2.9	16
16	<i>l</i> -Aminoacyl-triazine Derivatives Are Isoform-Selective PI3K $\hat{2}$ Inhibitors That Target Nonconserved Asp862 of PI3K $\hat{2}$. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 206-210.	1.3	27
17	Mechanisms of PI3K $\hat{2}$ -Selective Inhibition Revealed by Reciprocal Mutagenesis. <i>ACS Chemical Biology</i> , 2013, 8, 679-683.	1.6	19